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ORIGINAL ARTICLE
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through amelioration of NFAT-dependent endothelin-1 production  
in mice with acute Chagas cardiomyopathy
Matías Hernández1, Susana Wicz1, Miguel H Santamaría2, Ricardo S Corral3/+
1Universidad Nacional de San Luis, Facultad de Química, Bioquímica y Farmacia, Laboratorio de Biomedicina Molecular, San Luis, Argentina 
2Centro de Estudios Metabólicos, Laboratorio de Biología Experimental, Santander, Spain 
3Hospital de Niños Dr Ricardo Gutiérrez, Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas,  
Servicio de Parasitología-Chagas, Ciudad Autónoma de Buenos Aires, Argentina
BACKGROUND The anti-inflammatory and cardioprotective properties of curcumin (Cur), a natural polyphenolic flavonoid 
isolated from the rhizomes of Curcuma longa, are increasingly considered to have beneficial effects on the progression of Chagas 
heart disease, caused by the protozoan parasite Trypanosoma cruzi.
OBJECTIVE To evaluate the effects of oral therapy with Cur on T. cruzi-mediated cardiovasculopathy in acutely infected mice and 
analyse the in vitro response of parasite-infected human microvascular endothelial cells treated with this phytochemical.
METHODS Inflammation of heart vessels from Cur-treated and untreated infected mice were analysed by histology, with benznidazole 
(Bz) as the reference compound. Parasitaemia was monitored by the direct method. Capillary permeability was visualised by Evans-
blue assay. Myocardial ET-1, IL-6, and TNF-α mRNA expressions were measured by quantitative reverse transcription polymerase 
chain reaction (qRT-PCR). Microvascular endothelial HMEC-1 cells were infected in vitro with or without addition of Cur or Bz. 
Induction of the Ca2+/NFAT pathway was assessed by fluorometry, immunoblotting, and reporter assay.
FINDINGS Oral Cur therapy of recently infected mice reduced inflammatory cell infiltration of myocardial arteries without 
lowering parasite levels. Compared to that of the phosphate-buffered saline-receiving group, hearts from Cur-treated mice showed 
significantly decreased vessel inflammation scores (p < 0.001), vascular permeabilities (p < 0.001), and levels of IL-6/TNF-α (p < 
0.01) and ET-1 (p < 0.05) mRNA. Moreover, Cur significantly (p < 0.05 for transcript; p < 0.01 for peptide) downregulated ET-1 
secretion from infected HMEC-1 cells. Remarkably, Cur addition significantly (p < 0.05 at 27.0 μM) interfered with T. cruzi-
dependent activation of the Ca2+/NFATc1 signalling pathway that promotes generation of inflammatory agents in HMEC-1 cells.
CONCLUSIONS Oral treatment with Cur dampens cardiovasculopathy in acute Chagas mice. Cur impairs the Ca2+/NFATc1-
regulated release of ET-1 from T. cruzi-infected vascular endothelium. These findings identify new perspectives for exploring 
the potential of Cur-based interventions to ameliorate Chagas heart disease.
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Chagas disease, caused by infection with the pro-
tozoan parasite Trypanosoma cruzi, is a major cause 
of acute myocarditis and chronic cardiomyopathy in 
endemic areas of Latin America. The high rate of mi-
gration toward non-endemic countries has spread the 
infection to other continents. This human parasitosis is 
characterised by acute and chronic phases. The mortal-
ity rate of early Chagas disease is 5-10%, usually due to 
severe myocarditis or meningoencephalitis. Following 
initial infection, most patients enter into an asymptom-
atic, indeterminate stage, which lasts throughout life in 
the majority of hosts. The remaining 30% of infected in-
dividuals develop digestive or, more frequently, cardiac 
complications that may lead to stroke and sudden death, 
typically years or decades after initial infection.
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Chronic Chagas heart disease manifests itself as a 
dilated congestive cardiomyopathy associated with long-
term inflammation and fibrosis, cardiac hypertrophy 
and thromboembolic events. Heart failure in chroni-
cally infected hosts is the culmination of a pathologic 
process that begins during the acute phase of infection.
(1,2) The precise aetiology of this condition still remains 
elusive. To date, data from studies in animal models and 
humans support a multifactorial hypothesis comprising 
four central pathogenic mechanisms of T. cruzi-elicited 
cardiomyopathy: (i) parasite-dependent heart damage; 
(ii) immune-mediated myocardial injury; (iii) cardiac 
dysautonomia; and (iv) vascular dysfunction.(3)
Microvascular disturbances that modify blood distri-
bution in the cardiac muscle of Chagas patients contrib-
ute to cardiomyocyte destruction and ischaemia. This 
compromised microcirculation involves endothelial 
alterations, vasospasm, reduced blood flow, and focal 
ischaemia. Cardiovascular production of vasoactive me-
diators has been implicated in the pathogenesis of the 
vasculopathy seen in Chagas myocarditis.(4) One of the 
most relevant vasculitis-promoting factors triggered by 
T. cruzi infection is endothelin-1 (ET-1). Much of the evi-
dence suggests that this 21-amino acid peptide, produced 
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by cardiac and endothelial cells among others, plays a 
pivotal role in the development of Chagas heart disease.
(5-7) During the progression of parasite-driven cardiomy-
opathy, increased levels and activity of ET-1 may result 
in vascular injury, platelet aggregation, cardiac remodel-
ling, and enhanced secretion of inflammatory mediators 
that can adversely affect the myocardium.(5,8,9)
Given the well-demonstrated relationship between 
inflammation and Chagas pathogenesis, anti-inflam-
matory therapy is receiving increasing attention to im-
prove cardiovascular function in established heart dis-
ease caused by T. cruzi.(10) In this context, recent reports 
from different research groups, including our own, have 
shown that the anti-inflammatory and cardioprotective 
properties of curcumin (Cur), a natural polyphenolic fla-
vonoid isolated from the rhizomes of Curcuma longa, 
are beneficial to attenuate cardiac injury caused by this 
pathogen.(11-13) Current data further support the admin-
istration of Cur to improve vascular health.(14) Never-
theless, additional research is needed to determine the 
precise mechanisms involved in its therapeutic action 
against endothelial dysfunction. In this study, our goal 
was to evaluate the effects of oral therapy with Cur on T. 
cruzi-mediated cardiovasculopathy in acutely infected 
mice and analyse the in vitro response of parasite-infect-
ed human microvascular endothelial cells treated with 
this natural compound.
MATERIALS AND METHODS
Cell culture and infection - Human microvascular 
endothelial cells (HMEC-1, Center for Disease Control 
and Prevention, Atlanta, GA, USA) were maintained in 
MCDB-131 medium (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 2 mM L-glutamine, 1 μg/mL hydrocor-
tisone hemisuccinate, 10 ng/mL recombinant human epi-
dermal growth factor, 50 U/mL penicillin, 50 μg/mL strep-
tomycin, and 10% foetal bovine serum (Sigma-Aldrich, St. 
Louis, MO, USA). Cells were cultured at 37ºC in 5% CO2. 
HMEC-1 were not used beyond passage 7.
The vascular endothelial cells were infected for dif-
ferent intervals (4-24 h) with T. cruzi trypomastigotes 
(cell:parasite ratio 1:5), Tulahuen strain, in the presence 
and absence of Cur at a final concentration of 13.5 or 
27.0 μM (Fig. 1A). Cur (lot number 079K1756, purity ≥ 
94% curcuminoids and ≥ 80% curcumin by high per-
formance liquid chromatography) was purchased from 
Sigma-Aldrich. Endotoxin levels in the Cur preparations 
were undetectable (< 6.0 pg), as determined using a Lim-
ulus amoebocyte lysate analysis kit (Whittaker MA Bio-
products, Walkersville, MD, USA). In some experiments, 
HMEC-1 were incubated for 1 h in the presence and ab-
sence of ciclosporin A (CsA, 5 μM, Selleckchem, Munich, 
Germany) or Src kinase inhibitor-1 (Src-I1, 20 μM, Enzo 
Life Sciences, Lausen, Switzerland) before infection.
Quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) - Total RNA was extracted from 
HMEC-1/myocardial cells and treated with DNase I us-
ing the RNeasy® Micro kit (Qiagen, Hilden, Germany). 
mRNA levels of human and murine ET-1 were determined 
by qRT-PCR using cDNA, obtained from the reverse tran-
scription reactions, as template, with MyiQ™ Single-Color 
Real-Time PCR Detection System (Bio-Rad, Hercules, 
CA) and HotStart-IT® SYBR® Green One-Step qRT-PCR 
Master Mix Kit (Affymetrix, Santa Clara, CA, USA). The 
primer sequences that were used are as follows: human 
ET-1 forward, 5′-GCTCGTCCCTGATGGATAAA-3′ and 
reverse 5′-ATTCTCACGGTCTGTTGCCT-3′; mouse ET-1 
forward, 5′-TCCTCTGCCCGTCTGAACAAGAAA-3′ 
and reverse 5′-GCCATCAGCAATAGCATCAAGGCA-3′; 
18S forward, 5′-TCAAGAACGAAAGTCGGAGG-3′ and 
reverse, 5′-GGACATCTAAGGGCATCAC-3′.
Measurements of mouse pro-inflammatory cytokine 
(IL-6 and TNF-α) transcripts were also accomplished by 
qRT-PCR as described previously.(15) 18S rRNA served 
as an internal control to normalise the amount of cDNA 
present in each sample. The data were analysed using the 
comparative difference in cycle number (ΔCT) method 
according to the manufacturer’s instructions.
Measurement of endothelin-1 by enzyme-linked im-
munosorbent assay (ELISA) - ET-1 levels were deter-
mined in mouse serum samples collected on day 14 of 
infection/treatment, and 24 h supernatants from HMEC-
1 cultures, using the corresponding Quantikine ELISA 
Kit (R&D Systems, Abingdon, UK), according to the 
manufacturer’s guidelines. The threshold of sensitivity 
of the assay was 0.4 pg/mL.
Calcium determination by fluorescent dye - Para-
site-induced changes in intracellular calcium concentra-
tion ([Ca2+]i) in human endothelial cells were detected 
using the Ca2+-sensitive indicator Fura-2/AM as de-
scribed.(16) HMEC-1 loaded with 1 μM Fura-2/AM were 
incubated in the presence and absence of Cur at increas-
ing concentrations and infected with T. cruzi trypomas-
tigotes immediately thereafter. Cells treated with Cur 
only were used as controls. At the indicated times, the 
fluorescence signal was recorded with a spectrofluor-
ometer, with excitation and emission wavelengths at 340 
and 510 nm, respectively.
Immunoblot analysis - For western blotting experi-
ments, subcellular fractions from T. cruzi-infected vascu-
lar endothelial cells were generated as reported previous-
ly.(17) The purity of the fractions was verified by analysing 
marker proteins, including α-tubulin (cytoplasmic), and 
proliferating cell nuclear antigen (PCNA, nuclear). Im-
munoblotting was carried out as described elsewhere.
(16) Uninfected and infected HMEC-1, with or without 
Cur treatment, were disrupted; solubilised extracts (20 
μg) were separated on 6% sodium dodecyl sulphate-po-
lyacrylamide gels, and then transferred to nitrocellulose 
membranes. After blocking, the membranes were probed 
for 2 h at 37ºC with rabbit polyclonal antibody against the 
c1 isoform of nuclear factor of activated T cells (NFATc1, 
1:200, Santa Cruz Biotechnology, Dallas, TX, USA). The 
membranes were washed and incubated with secondary 
antibody (goat anti-rabbit IgG coupled to horseradish 
peroxidase; Jackson ImmunoResearch, West Grove, PA, 
USA) at 1:10,000 dilution, and the protein bands were 
visualised by a chemiluminescent peroxidase substrate 
(Amersham Pharmacia, Piscataway, NJ, USA).
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Fig. 1: experimental design. (A) In vitro evaluation of the therapeutic effect of curcumin (Cur, 0, 13.5, 27.0 µM) on Trypanosoma cruzi infection 
of human microvascular endothelial cells (HMEC-1). Intracellular calcium increase, NFAT activation, and endothelin-1 (ET-1) production were 
analysed at different times of infection. (B) In vivo evaluation of oral Cur therapy in C57BL/6 mice acutely infected with T. cruzi. Comparative 
analysis was made with infected mice receiving benznidazole, a reference standard drug against the parasite, or no drug treatment. Parasitae-
mia was measured at 8, 10, 12, and 14 days of infection. Mice were euthanised on day 14 post-infection, and hearts and serum specimens were 
obtained for histology, studies of vascular integrity, and expression of pro-inflammatory mediators.
Transfection and luciferase assays - NFAT transcrip-
tional activity was measured using an NFAT luciferase 
reporter [p(NFAT)3-luc] containing three tandem copies 
of the NFAT response element fused to the IL-2 mini-
mal promoter (a gift from M Fresno, Centro de Biología 
Molecular, Madrid, Spain). HMEC-1 were transfected 
essentially as described previously.(18) Briefly, exponen-
tially growing cells (4 × 104/well) were incubated with 
a mixture of 0.5 mg of the reporter plasmid and Lipo-
fectamine® LTX-containing Opti-MEM supplement-
ed with PLUS™ Reagent (Thermo Fisher Scientific, 
Waltham, MA, USA). In some experiments, the cells 
were co-transfected with 0.5 mg of the pSH102CD418 ex-
pression vector encoding an NFATc1 deletion mutant (1-
418) that functions as a dominant negative for all NFAT 
isoforms (dnNFAT, kindly provided by MA Iñiguez, 
Centro de Biología Molecular, Madrid, Spain).(16) The 
total amount of DNA in each transfection was kept con-
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stant by adding empty expression vector. Complete me-
dium was then added to the cells and incubated at 37ºC 
for 18 h. The transfected HMEC-1 were exposed to T. 
cruzi parasites (or not) without or with Cur at increasing 
concentrations, as indicated. The inhibitory effect of 1-h 
CsA pretreatment of the cells on NFAT transcriptional 
activity was also studied. The cells were harvested and 
lysed, and luciferase activity was measured by using a 
luciferase assay system with a luminometer (Monolight 
2010, Analytical Luminescence Laboratory, Ann Arbor, 
MI, USA). The transfection experiments were performed 
in triplicate. The luciferase activity data are presented 
as fold-induction [experimental relative luciferase units 
(RLU)/basal RLU in absence of any stimulus]. The re-
sults were normalised to extract protein concentrations 
measured with a Bradford assay kit.
Infection of mice - The Tulahuen strain of T. cruzi was 
maintained by weekly intraperitoneal inoculation of Swiss 
mice. Eight-week old C57BL/6 male mice (n = 30; Jackson 
Laboratories, Bar Harbor, ME, USA) were infected intra-
peritoneally with 103 blood trypomastigotes, keeping a 
group of ten uninfected animals as controls. Infected mice 
were divided into three sub-groups: 10 of them were treat-
ed with Cur, another 10 were treated with benznidazole 
(Bz), and the remaining 10 mice received phosphate-buff-
ered saline (PBS). Acute infection was verified by the de-
tection of parasites via direct blood examination at 8, 10, 
12, and 14 days post-infection (dpi). Mice were euthanised 
on day 14 post-infection, and hearts and serum specimens 
were collected for histology and ET-1 mRNA and protein 
analyses (Fig. 1B).
Cur treatment - One subset of ten chagasic mice was 
treated with Cur dissolved in corn oil (100 mg/kg body 
weight), administered daily by oral gavage from day 1 
through day 14 of infection (Fig. 1B). The dose was cho-
sen based on previous oral studies of the anti-inflamma-
tory effect of Cur in murine T. cruzi infection.(11,13) An-
other set of ten infected mice received oral therapy with 
Bz at 100 mg/kg body weight/day over the same period.
(19) Bz (lot number 1614, purity ≥ 99% by high perfor-
mance liquid chromatography), a reference standard drug 
against T. cruzi, was supplied by Laboratorio Elea, Bue-
nos Aires, Argentina. Ten infected mice received PBS.
Histological analysis of heart - Mouse cardiac tissues 
were bisected and placed in 10% neutral-buffered forma-
lin for at least 4 h at room temperature, followed by over-
night incubation in 70% ethanol. Samples were then em-
bedded in paraffin and semi-serial 5-μm tissue sections 
were prepared. Sections were deparaffinised, rehydrated, 
stained with haematoxylin and eosin, and examined by 
light microscopy at 200X and 400X magnification. A 
double-blind evaluation of the specimens was performed 
on randomised, precoded slides in a systematic fashion. 
For each animal, three myocardial sections were ana-
lysed, examining at least twenty areas per section (60 
microscopic fields examined). For the heart vessels [con-
duit (aorta) and distributing (medium- and small-sized) 
arteries], the inflammation score was graded as follows: 
0 for no inflammation or minimal number of inflamma-
tory cells; 1 for mild diffuse inflammatory infiltration or 
focal findings, involving < 25% of the vessel circumfer-
ence; 2 for moderate inflammatory infiltration or focally 
marked, involving 25-50% of the vessel circumference; 
and 3 for heavy inflammatory infiltration or focally 
marked, involving > 50% of the vessel circumference.(20)
Capillary permeability - Capillary permeability was 
measured using an Evans-blue assay, as reported previ-
ously.(21) The dye was extracted from the cardiac tissue 
Fig. 2: curcumin (Cur)-based therapy ameliorates cardiovascular pathology in mice with acute Trypanosoma cruzi infection. Heart specimens 
from T. cruzi-infected and uninfected C57BL/6 mice, orally treated with or without Cur or benznidazole (Bz) at 100 mg/kg body weight/day, were 
obtained. Three independent infections were conducted under the same conditions, each performed with ten mice per group. Microphotographs 
of histological analysis (haematoxylin and eosin staining) of cardiac tissues collected at 14 dpi are displayed. Top panels show heart vessels (A 
and C, 400X magnification) and aorta (B and D, 200X magnification) from uninfected mice, receiving (C-D) or not receiving (A-B) oral treatment 
with Cur. Scale bar is 100 μM. Bottom panels are representative images of heart distributing arteries (E, G and I, 400X magnification) and aorta 
(F, H and J, 200X magnification) from T. cruzi-infected mice, receiving (G-J) or not receiving (E-F) oral treatment with Bz (G-H) or Cur (I-J). 
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by incubation with formamide (70ºC for 24 h) and the 
concentration of Evans blue (expressed as μg dye per 
gram tissue) was estimated by dual-wavelength spectro-
photometry (620 and 740 nm).
Statistical data evaluation - Statistical analysis was 
performed using GraphPad Prism 5.0 software. Arith-
metic means and standard deviations of the means were 
calculated. Significant differences among groups were 
assessed by using one-way analysis of variance followed 
by Tukey’s post-hoc tests. A value of p < 0.05 was con-
sidered significant.
Ethics statement - This study was carried out in strict 
accordance with the recommendations of the Committee 
on the Ethics of Animal Experiments from Universidad 
Nacional de San Luis (UNSL, San Luis, Argentina), fol-
lowing the recommendations of the Guide for the Care 
and Use of Laboratory Animals of the National Institutes 
of Health (NIH Publications No. 8023, revised 1978; 
Rockville, MD, USA). The protocol was approved by the 
Institutional Committee on the Ethics of Animal Exper-
iments from UNSL (report #017-2405). All mice were 
maintained under pathogen-free conditions in our animal 
facilities. The individual room temperatures were kept 
at 18-22ºC with food and water ad libitum. A laboratory 
animal veterinarian was responsible for the care of the 
mice. The mice were euthanised in a CO2 chamber, and 
all efforts were made to minimise suffering.
RESULTS
Cur-based therapy ameliorates cardiovascular pa-
thology in acutely T. cruzi-infected mice - Mice bred on a 
C57BL/6 background, when infected with the Tulahuen 
strain of T. cruzi, are known to harbour abundant intra-
cellular parasites, exhibiting disseminated myonecrosis 
and severe microvascular compromise in cardiac tissue.
Fig. 3: effects of curcumin (Cur) treatment on parasitaemia, vascular inflammation and permeability, and myocardial pro-inflammatory cy-
tokine levels in acutely infected mice. (A) Parasitaemia was quantified by counting the number of circulating trypomastigotes in 5 μL of 
fresh blood collected from the tail vein at 8, 10, 12, and 14 days of infection. Results from infected mice receiving Cur, benznidazole (Bz), or 
phosphate-buffered saline (PBS) are depicted. ***p < 0.001 versus the remaining groups. (B) Inflammatory cell infiltration of heart vessels was 
histologically graded in tissue sections from the different uninfected and infected groups and expressed as a score, as described in Materials 
and Methods. *p < 0.05 and ***p < 0.001 between indicated groups. (C) Vascular permeability was measured by Evans blue dye assay. *p < 0.05 
and ***p < 0.001 between indicated groups. (D) IL-6 and TNF-α mRNA levels were analysed by quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) in total heart extracts from uninfected and infected (14 dpi) mice, treated with PBS, Cur, or Bz. *p < 0.05, **p < 0.01, 
and ***p < 0.001 between indicated groups. Values are expressed as means ± standard deviations from three independent infections conducted 
under the same conditions, each performed with ten mice per group.
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(5) In our hands, intense vasculitis of the aorta, as well as 
perivasculitis of the medium- and small-sized myocar-
dial arteries, was observed by day 14 of infection. Ac-
cumulation of inflammatory cells in the muscle tissue, 
in the aortic tunica media, and surrounding the vessel 
walls was evident in heart sections from acutely infected 
mice, whereas uninfected controls showed no histologi-
cal signs of cardiomyopathy, aortitis, or perivascular 
trauma (Fig. 2A-B, E-F). We next addressed whether 
the anti-inflammatory properties of Cur can modulate T. 
cruzi-elicited vasculopathy. Treatment of acute Chagas 
mice with Bz at a standard dose (100 mg/kg/d) attenuat-
ed inflammation of the heart vasculature, although some 
inflammatory infiltrates were observed (Fig. 2G-H). Cur 
administered to uninfected mice for 14 days did not af-
fect the histological features of their vessels (Fig. 2C-D). 
Along with the lack of adverse effects, oral Cur therapy 
(100 mg/kg/d) of recently infected mice substantially 
reduced inflammation of the myocardial arteries (Fig. 
2I-J) without modifying the bloodstream parasite bur-
den (Fig. 3A). In contrast, treatment with Bz led to a sig-
nificant (p < 0.001) drop in parasitaemia (Fig. 3A). The 
survival rate of untreated, Cur-treated, and Bz-receiving 
mice was 100% after 14 days of T. cruzi infection. The 
total vessel inflammation score was significantly (p < 
0.001) lower in hearts harvested from Cur-treated in-
fected mice compared to that from mice injected with 
trypomastigotes only (Fig. 3B). To confirm these obser-
vations, we further verified the occurrence of disrupted 
vascular integrity in our experimental model. Using an 
Evans blue assay, we examined whether oral administra-
tion of Cur could interfere with altered capillary perme-
ability in the myocardium after 14 days of infection. Ev-
ans blue dye, when injected into the bloodstream, binds 
to serum proteins, with the majority binding to albumin. 
If changes in vascular permeability occur, then the dye 
leaks from the vascular lumen into the interstitial tissue. 
The dye in the circulation is then washed out, and the 
tissues can be visually inspected for dye leakage. Treat-
ment of parasite-harbouring mice with Cur led to a sig-
Fig. 4: curcumin (Cur) attenuates endothelin-1 (ET-1) induction triggered by Trypanosoma cruzi infection. Top panels: ET-1 production was 
measured in T. cruzi-infected and uninfected mice, receiving or not receiving oral Cur/benznidazole (Bz) therapy (ten mice per group). (A) Cir-
culating ET-1 concentration was determined by enzyme-linked immunosorbent assay (ELISA) in serum samples collected from experimental 
groups treated with Cur, Bz, or phosphate-buffered saline (PBS). (B) RNA isolated from heart tissue at 14 dpi was used to perform quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) with specific primers, and normalised to ribosomal 18S RNA as described in Mate-
rials and Methods. Differences in ET-1 mRNA levels among the groups are expressed as fold increase. Values are presented as means ± standard 
deviations from three independent infections performed with ten mice per group. *p < 0.05 and **p < 0.01 between indicated groups. Bottom 
panels: Dose effect of Cur on ET-1 mRNA (C) and protein (D) expression triggered by T. cruzi infection of cultured human microvascular 
endothelial cells (HMEC-1). Cultures were parasite-infected (T. cruzi) in vitro for 4 h (for mRNA analysis) or 24 h (for soluble peptide measure-
ment) in the presence (+ Cur, 13.5 or 27.0 μM) or in the absence (+ PBS) of phytochemical. Non-infected cell preparations, either treated with 
PBS or the flavonoid at 27.0 μM (Cur), were included in the assays. Data are the means ± standard deviations of three independent experiments, 
each performed in triplicate. *p < 0.05; **p < 0.01; ***p < 0.001, between indicated groups.
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nificant (p < 0.001) improvement in vascular integrity in 
the heart when compared with that of untreated, infected 
mice (Fig. 3C). Moreover, Cur-based therapy caused a 
remarkable (p < 0.01) downregulation in cardiac pro-
inflammatory cytokine (IL-6, TNF-α) mRNA expres-
sion (Fig. 3D). At the doses used in this study, the early 
anti-inflammatory effect of Cur on the heart vasculature 
was as good as or even better than that achieved with Bz 
(Fig. 3B-D). Taken together, these results show that oral 
administration of Cur attenuates T. cruzi-dependent car-
diovasculopathy during acute murine infection.
Cur attenuates ET-1 induction triggered by T. cruzi 
infection - Upon parasite infection (14 dpi), an elevated 
serum concentration of ET-1, an important contribu-
tor to vascular compromise that is characteristic of T. 
cruzi-mediated cardiomyopathy(6,22), was demonstrated 
by ELISA in acute Chagas mice (Fig. 4A). This increase 
was paralleled by a three-fold enhanced ET-1 mRNA ex-
pression in the hearts of this group (Fig. 4B). In contrast, 
Cur-treated infected animals displayed a significant (p 
< 0.05) decline in myocardial transcripts and circulating 
levels of the ET-1 peptide compared with those measured 
in the untreated infected controls and in the acutely in-
fected mice under Bz therapy (Fig. 4A-B).
In addition, we tested the ability of Cur to inhibit T. 
cruzi-dependent generation of ET-1 by infected vascu-
lar endothelial cells.(23) The turmeric-derived chemical 
produced a concentration-dependent inhibition of ET-1 
mRNA and protein expression in HMEC-1 infected with 
T. cruzi trypomastigotes in vitro. Increased levels of ET-1 
mRNA (4-h infection) and soluble peptide (24-h infec-
tion) were respectively detected by qRT-PCR and ELISA 
in cell extracts and media from infected microvascular 
cells (Fig. 4C-D). Treatment with Cur at 27.0 μM, but 
not 13.5 μM, significantly (p < 0.05 for transcript and 
p < 0.01 for peptide analysis) attenuated the ET-1 up-
regulation upon parasite invasion. These observations 
indicate that the concentration-dependent effect of Cur 
on the vascular endothelium may interfere with the early 
production of the vasoconstrictor, ET-1 peptide, which is 
stimulated over the course of acute Chagas disease.
Cur impairs ET-1 production in T. cruzi-infected 
HMEC-1 through downregulation of the Ca2+-dependent 
NFAT signalling pathway - ET-1 biosynthesis in epithe-
lial and endothelial cells is regulated through specific in-
tracellular signal transduction pathways, including those 
mediated by Ca2+-sensitive NFAT and c-Src kinase.(24,25) 
Therefore, we investigated the involvement of these 
pathways in T. cruzi-induced ET-1 release from infected 
HMEC-1 using chemical inhibitors of each pathway. In-
creased ET-1 levels in the media from parasite-infected 
HMEC-1 were significantly (p < 0.05) attenuated by pre-
treatment of the cells with CsA, which blocks calcineu-
rin-dependent NFAT activation (Fig. 3A). Contrariwise, 
specifically inhibiting Src kinase with Src-I1(25) did not 
alter T. cruzi-induced ET-1 secretion. Addition of Cur to 
the infected endothelial cells reduced the release of the 
vasoactive peptide in a concentration-dependent man-
ner by up to 46% at 27.0 μM Cur (p < 0.05) (Fig. 5A). 
The HMEC-1 from all cultures retained viability after 
incubation with the different inhibitors [Supplementary 
data (Figure)]. These findings suggest that Cur down-
regulates ET-1 secretion from microvascular endothelial 
cells in response to chagasic infection by interfering 
with Ca2+/calcineurin/NFAT interaction.
It has been demonstrated that T. cruzi infection in-
duces a sustained elevation in [Ca2+]i in human endo-
thelial cells. We found that addition of Cur at 27.0 μM 
reduced the [Ca2+]i response in T. cruzi-harbouring 
HMEC-1 to the basal levels recorded in uninfected cells 
treated with Cur only. This inhibitory effect could not 
be achieved using 13.5 μM Cur (Fig. 5B). Coupled with 
NFAT elevation in HMEC-1, different stimuli may also 
lead to calcineurin-mediated NFAT dephosphorylation 
and translocation to the nucleus.(26) Immunoblot analysis 
demonstrated that T. cruzi infection induces NFATc1 ac-
tivation in vascular endothelial cells (Fig. 5C). However, 
cell treatment with Cur at increasing doses (13.5-27.0 
μM) prevented parasite-triggered NFATc1 nuclear trans-
location, thereby resulting in a progressive accumulation 
of cytoplasmic NFATc1 protein (Fig. 5C).
To further examine the cascade of NFAT activation 
promoted by T. cruzi in HMEC-1, we co-transfected the 
p(NFAT)3-luc reporter, carrying three NFAT response 
elements, with or without a dominant-negative dnNFAT 
plasmid. The expression of dnNFAT abrogated the patho-
gen-induced transcription of the reporter, supporting the 
involvement of NFAT in downstream signalling of the 
elevated [Ca2+]i in infected cells (Fig. 5D). A similar ef-
fect was observed in HMEC-1 treated with CsA, a po-
tent inhibitor of calcineurin-dependent NFAT induction. 
More importantly, Cur treatment significantly (p < 0.05 
at 27.0 μM) attenuated the increase in NFAT-dependent 
luciferase activity in response to infection. Collectively, 
the above results show that Cur is capable of abolishing 
the [Ca2+]i-associated activation of the NFATc1 isoform 
in vascular endothelial cells infected by T. cruzi.
DISCUSSION
During Chagas disease progression, the severity of 
chronic myocardial involvement appears to be related 
to the magnitude of acute heart injury.(1,2) Recently, we 
showed that Cur, the primary therapeutic curcuminoid 
derived from turmeric, can be effective in attenuating 
Chagas myocarditis.(13) In this study, we further found 
that in vivo oral treatment with Cur dampens cardiovas-
culopathy in mice recently infected with T. cruzi. The 
decrease in inflammation of heart vessels and vascular 
permeability observed with Cur-based therapy is most 
likely attributable to its downregulating effect on dif-
ferent inflammatory mediators, rather than direct tryp-
anocidal activity in vivo. No significant variation in the 
number of bloodstream parasites between mice with and 
without Cur treatment was recorded. Previously report-
ed data indicate that concentrations of Cur in mouse 
serum and tissues do not easily reach the parasiticidal 
level determined in vitro for this natural product.(11,12) 
Nevertheless, Cur might contribute to an adjunct therapy 
as it has been demonstrated to improve the anti-T. cru-
zi activity of Bz-based treatment.(12) In addition, Cur is 
known to interfere with the regulatory actions of T. cruzi 
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infection on several cardiopathogenic pathways linked 
to exacerbated production of cytokines, adhesion mo-
lecules, eicosanoids, natriuretic peptides, leukotrienes, 
and reactive oxygen/nitrogen species.(11,13)
Another relevant molecular target for Cur interven-
tion is ET-1, an important contributor to the vascular 
compromise that is characteristic of T. cruzi-mediated 
cardiomyopathy.(6,22) A growing body of literature has 
demonstrated key changes in the vascular reactivity to 
ET-1 in certain pathological conditions. Particularly, 
this vasoactive peptide has been shown to play a major 
role in the development of vascular disruption caused by 
Chagas and other infectious diseases.(27) In our series, 
acutely infected mice presented increased ET-1 levels in 
the circulation and cardiac tissue. T. cruzi-infected hosts 
frequently display elevated plasma levels of the peptide 
as well as augmented expression in the vasculature.(5,8,9) 
Moreover, ET-1 is increasingly recognised as a pro-in-
flammatory cytokine that promotes vasoconstriction, 
vascular permeability, platelet aggregation, and height-
ened production of adhesion molecules and inflammato-
ry agents, all of which have been tightly associated with 
Fig. 5: curcumin (Cur) impairs endothelin-1 (ET-1) production in Trypanosoma cruzi-infected human microvascular endothelial cells (HMEC-1) 
through downregulation of Ca2+-sensitive NFAT signalling. The involvement of Ca2+-dependent mechanisms in T. cruzi-promoted ET-1 release 
from infected HMEC-1 was verified. (A) Soluble ET-1 levels in the media of uninfected (PBS) or infected (T. cruzi) cells, cultured in the presence 
or in the absence of Cur at different concentrations (13.5 and 27.0 μM), were measured by enzyme-linked immunosorbent assay (ELISA). In some 
experiments, the cells were pre-treated for 1 h with chemical inhibitors of NFAT or c-Src kinase-mediated pathways (5 μM CsA or 20 μM Src-I1, re-
spectively), and their effect on ET-1 secretion was further determined. Data are the means ± standard deviations of three independent experiments, 
each performed in triplicate. *p < 0.05; **p < 0.01, versus untreated cells only infected with T. cruzi. (B) Calcium increase modulated by Cur was 
studied. HMEC-1 cells, exposed or not exposed to the parasite (Tc), were loaded with the Ca2+ indicator, Fura-2/AM, and changes in [Ca2+]i upon 
T. cruzi infection, performed in the presence or in the absence of Cur (13.5 or 27.0 μM), were recorded. Uninfected cells incubated with Cur at the 
highest dose only were used as a control. Arrows indicate the time (sec) when the parasite and/or the phytochemical were added. The results pre-
sented are representative of three independent experiments. (C) NFAT subcellular localisation was visualised by western blotting. HMEC-1 were 
infected with trypomastigotes, with or without addition of Cur at 13.5 or 27.0 μM, for 4 h. Fractionated extracts from both untreated and Cur-treated 
infected cells, as well as uninfected and untreated controls, were analysed. The phosphorylated cytosolic (P-NFATc1) or dephosphorylated nuclear 
(NFATc1) forms of the transcription factor and loading controls for cytosolic and nuclear proteins (α-tubulin and PCNA, respectively) are indicated. 
Cyto, cytosolic extracts; Nucl, nuclear extracts. One out of three separate experiments performed is shown. (D) The downstream cascade of NFAT 
activation promoted by T. cruzi in HMEC-1 was also examined. The cells were transiently transfected with the p(NFAT)3-luc reporter, carrying 
three NFAT response elements, alone or co-transfected with a dominant-negative NFAT (dnNFAT) plasmid. Cultures were then infected with the 
parasite (T. cruzi) and PBS or Cur at increasing doses (13.5, 27.0 μM) was added. In some experiments, HMEC-1 were treated with 5 μM CsA 
prior to infection. Transfected cells without treatment or trypomastigotes (PBS), or incubated with phytochemical only (Cur), were also assayed. 
Luciferase activity is expressed as fold induction (mean ± standard deviation) relative to that measured with empty vector-transfected cells. One out 
of three separate experiments performed is displayed. *p < 0.05; **p < 0.01 between indicated groups.
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Chagas cardiovasculopathy.(27) These alterations further 
contribute to the development of the typical dilated car-
diomyopathy observed in chronic symptomatic cases.(7)
Oral Cur therapy significantly reduced T. cruzi-de-
pendent induction of ET-1 and pro-inflammatory cy-
tokines (IL-6, TNF-α) in the infected mice. According to 
our experience, high-dose Cur administration seems to 
be more efficacious than the standard trypanocidal drug 
Bz in preventing early overproduction of heart-derived 
inflammatory mediators in infected mice. This regula-
tory effect accompanied the amelioration of vascular in-
flammation achieved by Cur treatment. In addition, we 
found that Cur particularly inhibits T. cruzi-dependent 
generation of ET-1 by infected vascular endothelial cells.
(23) Pharmacological interventions aimed at attenuating 
ET-1 synthesis and activities deserve consideration in 
the search for an effective strategy against cardiovascu-
lar inflammatory processes. Cur therapy has proven ef-
fective in modulating ET-1 levels and actions in both an-
imal models and clinical trials.(28) Our findings suggest 
that this regulatory ability could contribute to reducing 
T. cruzi-elicited vascular trauma.
We further demonstrated in vitro that Cur downregu-
lates ET-1 secretion from microvascular endothelial cells 
in response to chagasic infection by interfering with Ca2+/
NFAT-dependent signalling. To date, several cis-acting el-
ements have been characterised within the ET-1 promoter. 
Of note, two NFAT consensus sites (GGAAA) located in 
the distal upstream region are capable of binding NFATc1/
c3 isoforms and participating in transcriptional regulation 
of ET-1 gene expression.(24) The vascular endothelium is 
an important source of ET-1 upon T. cruzi infection.(5) 
Since early studies(23), a solid link has been established 
between parasite-stimulated synthesis and secretion of 
biologically active ET-1 from infected endothelial cells 
and subsequent vasospasms and cardiac remodelling. In 
the cardiovascular system, ET-1 is able to target differ-
ent cell types and trigger multiple intracellular signalling 
pathways implicated in the pathophysiology of Chagas 
disease, including those mediated by elevated [Ca2+]i lev-
els coupled to nuclear translocation of dephosphorylated 
NFAT.(29) Consistent with previously documented obser-
vations(30), we recently described a protective action of 
Cur involving the suppression of pathogenic prostaglan-
din E2/natriuretic peptide production through inhibition 
of the NFAT pathway in T. cruzi-harbouring cardiomyo-
cytes.(13) In addition, our findings herein suggest that Cur 
significantly impairs ET-1 secretion from T. cruzi-infect-
ed vascular endothelium, at least in part, by blocking the 
Ca2+/calcineurin/NFATc1 cascade.
Trypomastigote-endothelial cell interactions are 
among the first to occur during the initial phase of T. 
cruzi infection and have been identified as a critical step 
in Chagas pathogenesis. Treatment of vascular and, in 
particular, microvascular dysfunction might be impor-
tant to help mitigate not only Chagas heart disease but 
also other infectious and non-infectious cardiomyopa-
thies. The results from this study unveil a putative mech-
anism of action of Cur involving inhibition of the Ca2+/
NFAT-dependent secretion of the cardiopathogenic ET-1 
peptide by T. cruzi-infected vascular endothelium. This 
targeted effect could partly account for the marked reduc-
tion in inflammatory injury observed in the myocardial 
vessels and tissues from acutely infected mice subjected 
to oral Cur therapy. Our current and previous(13) findings 
provide new perspectives for exploring the therapeutic 
potential of this multifunctional phytochemical to reduce 
parasite-driven vasculitis and myocarditis. Despite the 
morbidity and mortality inflicted by Chagas disease, eti-
ologic treatment still relies on only two drugs, nifurtimox 
and Bz. Furthermore, due to the well- known toxicity and 
limited effects in prolonged symptomatic infection with 
the currently used drugs, research and development of 
novel, non hazardous medications with enhanced effica-
cy is urgently needed to treat the large population infec-
ted with this pathogen. Over the last decade, numerous 
molecules, both natural and synthetic, have been postu-
lated for Chagas disease chemotherapy, but their unsuita-
ble and undesirable structural and pharmacokinetic prop-
erties have precluded further development. Therefore, 
the potent anti-inflammatory and cardio/vasoprotective 
actions, low cost, advantageous oral administration, and 
outstanding safety profile evidenced by Cur deserve at-
tention to highlight this phytochemical as a complemen-
tary tool to the limited array of therapies so far available 
for the treatment of Chagas cardiomyopathy.
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